Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer

Conclusion The combination of Docetaxel, Celecoxib, and Zoledronic acid failed to improve OS or to offer an acceptable biologic response. We do not believe that there is compelling evidence to include either Celecoxib or Zoledronic acid in further phase II/III trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

CONCLUSIONS: Based on safety and tolerability, mivebresib RP2D is 1.5mg for the daily schedule, 2.5mg for 4/7 and 3mg for M-W-F. Mivebresib has a tolerable safety profile and stable disease was observed in some patients with malignant solid tumors. PMID: 31420359 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conclusion: The safety profile of cabazitaxel in this pooled analysis of two cabazitaxel early access programmes was manageable and consistent with previous Phase III trials (TROPIC, PROSELICA). PMID: 31289614 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion: Higher pretreatment RDW levels were demonstrated to be associated with poor clinical outcome in male LSCC patients and might be novel markers for patient stratification in LSCC management. Introduction Laryngeal cancer is one of the most common cancers of the head and neck, of which the estimated crude incidence and mortality rates in China were 1.86/100,000 and 1.01/100,000, respectively (1). This disease has a male predominance with a male-to-female ratio of 20 to 30:1 in China (2). The most commonly observed histological type of laryngeal cancer is laryngeal squamous cell cancer (LSCC), accounting for ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Tasquinimod is associated with better rPFS in mCRPC. The toxicity of tasquinimod requires further investigation, it is not recommended for routine clinical use.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Conclusions AMG 900 40  mg/day with G-CSF had manageable toxicity and demonstrated single-agent activity in patients with heavily pretreated, chemotherapy-resistant ovarian cancer.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
ConclusionsOnce-daily seviteronel was generally well tolerated in women with and 450  mg QD was chosen as the RP2D.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D. PMID: 29744674 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Res Treat Source Type: research
In 2011, we introduced the Mi-Oncoseq program, an IRB-approved protocol to carry out integrative sequencing of advanced cancer patients. It was one of the first comprehensive DNA and RNA sequencing programs offered for cancer patients. The purpose of this program was to determine the utility of genomic sequencing of tumors and germline coupled with a multi-disciplinary Precision Medicine Tumor Board (PMTB) in the management of advanced cancer patients. Collectively across all patient cohorts we have enrolled over 1500 patients since inception of Mi-Oncoseq where molecular results for both somatic and germline aberrations a...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Keynote Presentations: Oral Presentations - Invited Abstracts Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Celebrex | Docetaxel | Drugs & Pharmacology | Investigational New Drugs | Neurology | Oral Cancer | Palliative | Palliative Care | Prostate Cancer | Reclast | Study | Taxotere | Toxicology | Zometa